Dr Malone said in a recent interview that the FDA asked–not required– the vax manufacturers to study ADE but they declined.
The segment on ADE is in the first few minutes of this interesting interview
from the accompanying text.
Malone said he found it especially “shocking” that the FDA never insisted that Pfizer rule out the historical problem associated with spike-based coronavirus vaccines, a phenomenon called vaccine enhanced infection of disease (a subset is called antibody-dependent enhancement). It’s a problem that created a huge fiasco in the Philippines in 2017 when several lawmakers and health officials were indicted for their roles in promoting Sanofi’s Dengvaxia vaccine that led to the deaths of hundreds of vaccinated Philippine children who developed a particularly severe reaction to the Dengue virus when they encountered the real virus after vaccination against it.
While the agencies were well aware of the danger, they never insisted on trials being conducted or data proving that the vaccines were free of the potentially devastating risk, “so we don’t know at this point whether or not there is vaccine-enhanced disease going on with these vaccines. There are some signs in the data particularly with delta, that this remains a possibility,” Malone said.